Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-δ,γ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab

Carla Casulo, MD, Juan-Manuel Sancho, Koen Van Eygen, MD, Sven de Vos, MD PhD, Santiago Mercadal, MD, Roderick J. Johnson, MD, Kamal Bouabdallah, MD, Houston Holmes, MD FACP, Jan Lemmens, MD, Emmanuel Gyan, MD, Michele Merli, MD, Ranjana H Advani, MD, Lori Steelman, MA, Joseph Pearlberg, MD PhD, Andre Goy, MD

Blood (2016) 128 (22): 2979.

https://doi.org/10.1182/blood.V128.22.2979.2979

Published: 2016

Journal Articles

Mantle Cell Lymphoma Management and Outcome in the U.K's Population-Based Haematological Malignancy Research Network

Russell Patmore, MRCP FRCPath, Alexandra Smith, PhD, Simon Appleton, Debra Howell, PhD, Roderick J. Johnson, MD, Cathy H Burton, Eve Roman, PhD

Blood (2016) 128 (22): 1112.

https://doi.org/10.1182/blood.V128.22.1112.1112

Published: 2016

Journal Articles

Outcomes With Rituximab Monotherapy Versus R-CHOP In Post-Transplant Lymphoproliferative Disease Arising After Solid Organ Transplant: A Multicentre UK Study

David Burns, Katherine Clesham, Joanna Haughton, Michelle Lannon, Hayder Hussein, Jennifer Marsh, Martin Rowe, Anne L Lennard, Roderick J Johnson, Kate Cwynarski, Sridhar Chaganti

Blood (2013) 122 (21): 3043.

https://doi.org/10.1182/blood.V122.21.3043.3043

Published: 2013

Journal Articles

A Phase 1 Trial of Escalating High Dose Methotrexate Supported by Glucarpidase to Treat Patients with Primary Central Nervous System Lymphoma (PCNSL). (CRUK/08/010)

Roderick J. Johnson, MD, Andrew Davies, MD, Siow-Ming Lee, MD, Dianne Gilson, MD, Paul Smith, PhD, Wendi Qian, Nivette Braganca, Nadjet El-mehidi, Peter Johnson

Blood (2012) 120 (21): 4850.

https://doi.org/10.1182/blood.V120.21.4850.4850

Published: 2012

Journal Articles

A Phase II Clinical Trial of Fludarabine and Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic Lymphoma (AITL), an NCRI Clinical Trial. CRUK C17050/A5671

William M Townsend, MRCP, Roderick J. Johnson, MD, Nicholas Counsell, Humra Shah, Bryson Pottinger, Katy Evans, Caroline Wickham, Paul Smith, Rudin Claudius, MD FRCP FRCPath

Blood (2012) 120 (21): 3642.

https://doi.org/10.1182/blood.V120.21.3642.3642

Published: 2012

Journal Articles

Thalidomide Maintenance Following High Dose Therapy in Multiple Myeloma: A UK Myeloma Forum Phase 2 Study.

Sylvia Feyler, MD, Andy Rawstron, PhD, Graham Jackson, MD, John Snowden, MD, Kim Hawkins, PhD, Roderick J. Johnson, MD

Blood (2005) 106 (11): 641.

https://doi.org/10.1182/blood.V106.11.641.641

Published: 2005

Journal Articles

Circulating Primitive Stem Cells in Paroxysmal Nocturnal Hemoglobinuria (PNH) Are Predominantly Normal in Phenotype But Granulocyte Colony-Stimulating Factor Treatment Mobilizes Mainly PNH Stem Cells

Roderick J. Johnson, Andy C. Rawstron, Steve Richards, Gareth J. Morgan, Derek R. Norfolk, Sheila O'Connor, and Peter Hillmen

Blood (1998) 91 (12): 4504–4508.

https://doi.org/10.1182/blood.V91.12.4504

Published: 1998

NARROW

Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-δ,γ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab

Mantle Cell Lymphoma Management and Outcome in the U.K's Population-Based Haematological Malignancy Research Network

Outcomes With Rituximab Monotherapy Versus R-CHOP In Post-Transplant Lymphoproliferative Disease Arising After Solid Organ Transplant: A Multicentre UK Study

A Phase 1 Trial of Escalating High Dose Methotrexate Supported by Glucarpidase to Treat Patients with Primary Central Nervous System Lymphoma (PCNSL). (CRUK/08/010)

A Phase II Clinical Trial of Fludarabine and Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic Lymphoma (AITL), an NCRI Clinical Trial. CRUK C17050/A5671

Thalidomide Maintenance Following High Dose Therapy in Multiple Myeloma: A UK Myeloma Forum Phase 2 Study.

Circulating Primitive Stem Cells in Paroxysmal Nocturnal Hemoglobinuria (PNH) Are Predominantly Normal in Phenotype But Granulocyte Colony-Stimulating Factor Treatment Mobilizes Mainly PNH Stem Cells

Email alerts

ASH Publications

American Society of Hematology

Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-δ,γ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab

Mantle Cell Lymphoma Management and Outcome in the U.K's Population-Based Haematological Malignancy Research Network

Outcomes With Rituximab Monotherapy Versus R-CHOP In Post-Transplant Lymphoproliferative Disease Arising After Solid Organ Transplant: A Multicentre UK Study

A Phase 1 Trial of Escalating High Dose Methotrexate Supported by Glucarpidase to Treat Patients with Primary Central Nervous System Lymphoma (PCNSL). (CRUK/08/010)

A Phase II Clinical Trial of Fludarabine and Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic Lymphoma (AITL), an NCRI Clinical Trial. CRUK C17050/A5671

Thalidomide Maintenance Following High Dose Therapy in Multiple Myeloma: A UK Myeloma Forum Phase 2 Study.

Circulating Primitive Stem Cells in Paroxysmal Nocturnal Hemoglobinuria (PNH) Are Predominantly Normal in Phenotype But Granulocyte Colony-Stimulating Factor Treatment Mobilizes Mainly PNH Stem Cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only